Prostate cancer comes in various forms and has proven difficult to treat. Provided herein are various methods and compositions for treating all forms of prostate cancers with dopa decarboxylase (DDC) inhibitors. These dopa decarboxylase inhibitors include carbidopa (.alpha.-Methyl-dopahydrazine), MFMD (.alpha.-monofluoromethyldopa), NSD-1015 (3-hydroxybenzylhydrazine), Methyldopa (L-.alpha.-Methyl-3,4-dihydroxyphenylalanine) or benserazide, and the inhibitors may be used in combination. DDC inhibitors may also be used to inhibit the progression of prostate cancer to androgen-independence and neuroendocrine prostate cancer.

The University of British Columbia

Treatment of prostate cancer with DDC inhibitor

Metastatic cancer cells originating from gastric cancer are detected by a method comprising the step of collecting a biological sample from a subject, the step of detecting the presence of at least either aldehyde dehydrogenase or dopa decarboxylase in the biological sample of the subject, and the step of determining that the possibility of containing metastatic cancer cells originating from the gastric cancer in the sample is high when at least either aldehyde dehydrogenase or dopa decarboxylase is present. By the use of these as markers for metastatic cancer cells originating from gastric cancer, the presence or absence of peritoneal metastasis in a gastric cancer patient can be detected rapidly and reliably, and data important for deciding whether intraperitoneal cancer chemotherapy should be applied is provided.

dopa decarboxylase/neoplasms

Treatment of prostate cancer with DDC inhibitor

Method of detecting metastasizing cancer cells originating in stomach cancer

The most complete medicinal herbs database backed by science